Ethmozin: A new antiarrhythmic agent developed in the USSR. Efficacy and tolerance

Abstract

Ethmozin, a phenothiazine derivative, was developed in the Soviet Union as a new antiarrhythmic agent. We evaluated ethmozin using a controlled single-blinded in-hospital protocol in 14 ambulatory patients with ventricular ectopy ranging from an average of 48 to 1,801 depolarizations per hour and in eight patients with atrial ectopy ranging from 63 to 693 depolarizations per hour. Placebo was administered for the first 3 days, followed by ethmozin from 2.4 to 11.2 mg./Kg./day administered orally every 8 hours for 7 days and concluding with placebo for the final 3 days. Continuous 24-hour long-term electrocardiographic monitoring for 13 days was employed to measure drug efficacy accurately. Six of eight (75 per cent) patients with atrial ectopy and 10 of 14 (71 per cent) patients with ventricular ectopy had statistically significant reductions in ectopy during ethmozin therapy. Atrial ectopy was reduced at a lower dose and plasma level of ethmozin than was ventricular ectopy. With the exception of mild nausea in one patient, no side effects of ethmozin therapy were noted. Ethmozin appears to be a well-tolerated, effective antiarrhythmic agent with a dosage regimen that can promote patient compliance for long-term use.